The numbers reflect that demand. Global healthcare metaverse market projections show growth from $504.8 million in 2020 to $5.37 billion by 2030, a 48.3% CAGR that no enterprise can afford to treat as background noise. But the more telling signal is directional: every healthcare enterprise AI solution, from digital health consulting to AI-powered automation in clinical workflows, is converging on the same goal. Give patients more control, give providers better information, and close the gap between what the system costs and what it delivers. The metaverse, combined with enterprise AI applications and generative AI development, is one of the few technologies positioned to advance all three simultaneously.
Get ready for telehealth 2.0
Think about what telehealth actually promised a decade ago. A video call with a doctor. Convenient, sure, but not transformative. What’s emerging now is fundamentally different in kind, not just degree.
Through the combination of AI and VR/AR, virtual platforms create clinical environments that go far beyond the screen. A physician at Johns Hopkins performed surgery guided by CT scan images projected directly over the patient’s body via an AR headset. Cambridge University Hospitals built the world’s first mixed-reality training application, letting medical students interact with holographic patients. A separate study found that patients immersed in VR required less anesthesia during surgery. These aren’t proofs of concept anymore. They’re early indicators of a care delivery model where enterprise AI solutions close the gap between physical presence and remote access.
The numbers follow the science. The global healthcare metaverse market is projected to grow from $504.8 million in 2020 to $5.37 billion by 2030, a 48.3% CAGR. Healthcare providers and pharma companies are already building in connected health, clinical trials, data interoperability, and 360-degree patient views. Digital therapeutics services are advancing patient management for chronic pain, diabetes, and mental health conditions at a scale that traditional delivery never reached.
And this is where digital transformation with AI stops being a strategy conversation and starts becoming an execution one. The infrastructure, the AI engineering, the data platforms, they all have to be built for it.
How virtual experiences will make a difference in healthcare
Three forces are converging right now in healthcare: the push for digital therapeutics, the maturation of clinical trial technology, and the accelerating shift to value-based care. Virtual platforms sit at the intersection of all three, and the implications are significant.
Start with digital therapeutics. AI-powered applications running inside immersive environments can do something traditional care delivery can’t: continuously observe patient behavior at scale. A gamified app built for children in foster care, for instance, captures behavioral signals through play patterns rather than clinical interviews. Earlier detection, fewer on-site visits, and a more humane experience for vulnerable populations. That’s digital therapeutics with real consequence.
Clinical trials tell a similar story. Decentralized, home-based trials are already reshaping how pharmaceutical companies conduct research, and digital twins are making those trials faster and more statistically rigorous. Machine learning-generated virtual patient models let researchers predict disease progression, optimize dosing protocols, and scale across diverse populations without the logistical constraints of traditional settings. The supply chain complexity that comes with dispersed trial participants becomes visible and manageable when digital twins connect every stakeholder in real time.
And then there’s value-based care. AI-driven virtual agents handling routine coverage and claims inquiries free human specialists for the conversations that actually require judgment. Health insurers get a more cost-effective support model; beneficiaries get faster, more personalized responses. Both outcomes matter if the 2030 goal of enrolling 63 million Medicare beneficiaries in value-based models is to be achieved.
Connected telehealth through digital therapeutics, digital twins in clinical development, and virtual-first value-based care aren’t distant possibilities. They’re the three channels through which enterprise AI solutions and digital transformation with AI are already beginning to reshape care delivery.
Connected telehealth through digital therapeutics
Digital therapeutics is where the metaverse stops being theoretical and starts doing clinical work. At its core, DTx uses evidence-based software to prevent, manage, or treat medical conditions, and virtual platforms give it the delivery mechanism it’s always needed. Chronic pain, diabetes, cognitive behavioral therapy for anxiety: these aren’t conditions a quarterly office visit can adequately address. Continuous, immersive engagement can.
That’s the premise behind our work in this space. Using AI and generative application development principles, we built a gamified metaverse app designed to surface mental health signals in children, particularly those in foster care. Children enter a colorful, low-pressure gaming environment. Caregivers observe behavioral patterns, when a child logs in, how long they engage, where they disengage, to identify early indicators of anxiety or isolation. No on-site visit required. No clinical setting to navigate.
But the architecture is what makes it genuinely scalable. A companion mobile app extends reach to parents and teachers, and the underlying platform adapts to other contexts, schools, workplaces, community programs. That kind of digital transformation with AI at its foundation is what separates a proof of concept from a program with legs.
For enterprise AI applications in healthcare, this is a sharper argument than most: the path to affordability and access doesn’t run only through better billing systems. Sometimes it runs through a leaderboard.
Digital twins boost clinical trials
Clinical trials have always been complex. But decentralized, home-based trials introduce a supply chain so dispersed, so multi-stakeholder, that traditional oversight simply can’t keep pace. Digital twins change that equation. By generating virtual patient models through machine learning, pharma companies can simulate therapy responses, predict disease progression, and build statistical power without waiting on real-world data alone. Alzheimer’s researchers are already doing this with ML models that produce virtual twins statistically indistinguishable from actual patients. Speed up research, yes. But the bigger gain is decision quality. When every variable in a trial can be modeled across diverse virtual patient populations, the insights that shape drug development get sharper. Brillio’s work with a decentralized clinical trials client takes this further. Applying digital twin technology to a fragmented supply chain spanning individual test subjects, pharma manufacturers, and logistics providers, we created a connected view where every stakeholder becomes visible in real time. That kind of enterprise AI application in life sciences is exactly what smart clinical trials for lifescience demand today: not just data collection, but a live, intelligent model of the entire trial ecosystem. Digital twins become the connective layer that transforms isolated data points into a coherent, actionable picture. For organizations asking how to implement enterprise AI solutions in complex, multi-party research environments, this is where the answer starts to take shape.
Value-based care goes virtual
Value-based care is already reshaping how Medicare operates. When CMS set a goal to bring all 63 million Medicare beneficiaries into value-based models by 2030, it put enormous pressure on insurers to perform at scale without proportionally scaling costs. That tension is where the metaverse becomes genuinely interesting.
Virtual platforms give health insurers a new support channel, one that does more than replicate the telephone. AI-powered virtual agents can field beneficiary questions on coverage, claims, and care options in real time, drawing on connected knowledge bases to deliver accurate, contextual answers. For insurers, this isn’t just a cost play. It frees human agents to handle what genuinely requires human judgment, concentrating expertise where it counts.
But the deeper value is experiential. Healthcare digital transformation consulting work consistently shows that member satisfaction tracks closely with how supported people feel between care touchpoints. A virtual environment, built on enterprise AI applications and conversational interfaces, can deliver that sense of availability without the overhead of always-on staffing. It’s personalized in a way telephone queues never were.
The result is a model where quality of care and cost efficiency move in the same direction. Virtual platforms don’t just answer questions; they build the kind of continuous, low-friction engagement that value-based care actually requires to succeed. For insurers navigating tighter margins and higher member expectations simultaneously, that combination is hard to ignore.
